Sign In
Buy NERV
$3.98
-0.0400 (-1.00%)
At Close: Jul 31, 2026
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
08:30am, Wednesday, 28'th Jun 2023
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
10:57am, Friday, 09'th Jun 2023
Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
02:11pm, Monday, 05'th Jun 2023
Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead
05:34pm, Friday, 19'th May 2023
NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispu
What Makes Minerva Neurosciences (NERV) a New Buy Stock
01:02pm, Thursday, 18'th May 2023
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
07:30am, Monday, 15'th May 2023
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 202
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
08:30am, Monday, 08'th May 2023
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript
11:31am, Wednesday, 08'th Mar 2023
Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Fred Ahlholm - CFO Conference Cal
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
07:30am, Wednesday, 08'th Mar 2023
Company to Host Conference Call Today at 8:30 a.m. ET Company to Host Conference Call Today at 8:30 a.m. ET
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
08:30am, Wednesday, 01'st Mar 2023
Management to Host Conference Call Management to Host Conference Call
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
12:02pm, Thursday, 29'th Dec 2022
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript
10:02am, Wednesday, 09'th Nov 2022
Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Frederick Ahlholm - CFO Confer
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
08:30am, Wednesday, 02'nd Nov 2022
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne
Minerva Neurosciences to request meeting with FDA about schizophrenia drug
08:51am, Monday, 17'th Oct 2022
Minerva Neurosciences Inc. NERV, +7.61% said Monday that it received a refusal to file letter from the Food and Drug Administration for its application for roluperidone as a treatment for patients wit
